Technology Pioneers 2015 ⎢Keith Murphy ⎢ Organovo

TL;DR

Organovo combines mechanical engineering, software engineering, and cell biology to create innovative 3D bioprinting solutions, leading to breakthroughs in various biological areas and offering the potential to revolutionize drug development and transplantation.

Transcript

so there's a few things that are unique about organovo as a company and the first is that we sit at the interface of a number of different technical disciplines and it really took an advancement in getting all these disciplines to work together to get to some of the technical opportunities that we've had so we bring together mechanical engineering ... Read More

Key Insights

• 👻 Organovo's integration of mechanical engineering, software engineering, and cell biology allows them to create innovative 3D bioprinting solutions.
• 🥺 Their application of 3D bioprinting to different tissues leads to breakthroughs and insights not achievable with traditional methods.
• 🎟️ Organovo's sense of mission and focus on patient impact drives their development of drug models and transplantable tissues.
• ☠️ By offering a better predictive model of disease, 3D bioprinting has the potential to revolutionize drug development and reduce failure rates.

Questions & Answers

Q: What makes Organovo's approach to 3D bioprinting unique?

Organovo stands out by integrating mechanical engineering, software engineering, and cell biology, allowing them to create novel 3D bioprinting solutions that surpass traditional methods like cell culture in petri dishes.

Q: In what areas has Organovo seen breakthroughs with their 3D bioprinting technology?

Organovo has experienced breakthroughs in various areas, including lung tissue, liver tissue, and kidney tissue. By recreating functional human tissue outside the body, they uncover insights not achievable with traditional cell culture methods.

Q: What drives Organovo's motivation as a company?

Organovo's team is motivated by their sense of mission to impact patients. In the short term, they focus on developing innovative drug models to replace animal models. In the long term, they aim to offer transplantable tissues to treat specific medical conditions.

Q: How can 3D bioprinting help address the failure rate of new drugs?

3D bioprinting provides a better predictive model of disease outside the body, reducing the reliance on animal models. By improving the drug selection process, Organovo's bioprinted tissues have the potential to offer faster and more cost-effective drug solutions.

Summary & Key Takeaways

• Organovo brings together different technical disciplines to advance 3D bioprinting and create functional human tissue outside the body.

• By applying their technology to various tissues such as lung, liver, and kidney, Organovo has achieved breakthroughs that were previously unattainable.

• The company's sense of mission and focus on impacting patients drives their development of innovative drug models and tissues for transplantation.